Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 194

1.

Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer.

Cortes J, Montero AJ, Glück S.

Cancer Treat Rev. 2012 Apr;38(2):143-51. doi: 10.1016/j.ctrv.2011.03.006. Epub 2011 May 8. Review.

PMID:
21550727
2.

A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies.

Goel S, Mita AC, Mita M, Rowinsky EK, Chu QS, Wong N, Desjardins C, Fang F, Jansen M, Shuster DE, Mani S, Takimoto CH.

Clin Cancer Res. 2009 Jun 15;15(12):4207-12. doi: 10.1158/1078-0432.CCR-08-2429. Epub 2009 Jun 9.

3.

Eribulin mesylate in the management of metastatic breast cancer and other solid cancers: a drug review.

Polastro L, Aftimos PG, Awada A.

Expert Rev Anticancer Ther. 2014 Jun;14(6):649-65. doi: 10.1586/14737140.2014.920693. Review.

PMID:
24852360
4.

Eribulin mesylate for the treatment of late-stage breast cancer.

Gourmelon C, Frenel JS, Campone M.

Expert Opin Pharmacother. 2011 Dec;12(18):2883-90. doi: 10.1517/14656566.2011.637490. Epub 2011 Nov 17. Review.

PMID:
22087618
5.

Eribulin mesylate for the treatment of breast cancer.

Cigler T, Vahdat LT.

Expert Opin Pharmacother. 2010 Jun;11(9):1587-93. doi: 10.1517/14656566.2010.486790. Review.

PMID:
20450446
6.

Eribulin mesylate: a novel halichondrin B analogue for the treatment of metastatic breast cancer.

McBride A, Butler SK.

Am J Health Syst Pharm. 2012 May 1;69(9):745-55. doi: 10.2146/ajhp110237. Review.

PMID:
22517020
7.

Review on the clinical use of eribulin mesylate for the treatment of breast cancer.

Aseyev O, Ribeiro JM, Cardoso F.

Expert Opin Pharmacother. 2016;17(4):589-600. doi: 10.1517/14656566.2016.1146683. Epub 2016 Feb 17. Review.

PMID:
26809667
8.

Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine.

Cortes J, Vahdat L, Blum JL, Twelves C, Campone M, Roché H, Bachelot T, Awada A, Paridaens R, Goncalves A, Shuster DE, Wanders J, Fang F, Gurnani R, Richmond E, Cole PE, Ashworth S, Allison MA.

J Clin Oncol. 2010 Sep 1;28(25):3922-8. doi: 10.1200/JCO.2009.25.8467. Epub 2010 Aug 2.

PMID:
20679609
9.

Eribulin: rediscovering tubulin as an anticancer target.

Jimeno A.

Clin Cancer Res. 2009 Jun 15;15(12):3903-5. doi: 10.1158/1078-0432.CCR-09-1023. Epub 2009 Jun 9.

10.

Eribulin mesylate (E7389): review of efficacy and tolerability in breast, pancreatic, head and neck, and non-small cell lung cancer.

Scarpace SL.

Clin Ther. 2012 Jul;34(7):1467-73. doi: 10.1016/j.clinthera.2012.06.003. Epub 2012 Jun 25. Review.

PMID:
22739019
11.

Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.

Vahdat LT, Pruitt B, Fabian CJ, Rivera RR, Smith DA, Tan-Chiu E, Wright J, Tan AR, Dacosta NA, Chuang E, Smith J, O'Shaughnessy J, Shuster DE, Meneses NL, Chandrawansa K, Fang F, Cole PE, Ashworth S, Blum JL.

J Clin Oncol. 2009 Jun 20;27(18):2954-61. doi: 10.1200/JCO.2008.17.7618. Epub 2009 Apr 6.

PMID:
19349550
12.

Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer.

Ates O, Babacan T, Kertmen N, Sarici F, Cenoli A, Akin S, Karakas Y, Kilickap S, Ozisik Y, Sever AR, Aksoy S, Altundag K.

J BUON. 2016 Mar-Apr;21(2):375-81.

PMID:
27273947
13.

Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial.

Morgan RJ, Synold TW, Longmate JA, Quinn DI, Gandara D, Lenz HJ, Ruel C, Xi B, Lewis MD, Colevas AD, Doroshow J, Newman EM.

Cancer Chemother Pharmacol. 2015 Nov;76(5):897-907. doi: 10.1007/s00280-015-2868-7. Epub 2015 Sep 11.

14.

Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer.

McIntyre K, O'Shaughnessy J, Schwartzberg L, Glück S, Berrak E, Song JX, Cox D, Vahdat LT.

Breast Cancer Res Treat. 2014 Jul;146(2):321-8. doi: 10.1007/s10549-014-2923-9. Epub 2014 Apr 4. Erratum in: Breast Cancer Res Treat. 2014 Jul;146(2):329.

15.

Advances in therapy: eribulin improves survival for metastatic breast cancer.

Morris PG.

Anticancer Drugs. 2010 Nov;21(10):885-9. doi: 10.1097/CAD.0b013e32833ed62e. Review.

PMID:
20838209
16.

Effectiveness and safety of eribulin mesylate: a new therapeutic option in the treatment of metastatic breast cancer.

O'Sullivan Coyne G, Walsh J, Kelly CM.

Expert Opin Drug Saf. 2012 Jul;11(4):643-50. doi: 10.1517/14740338.2012.698608. Epub 2012 Jun 14.

PMID:
22694309
17.

[Clinical evaluation of eribulin mesylate for the treatment of metastatic breast cancer].

Matsuzaki H, Tohnosu N, Yoshiwara C, Maruyama T, Tanaka H, Natsume T, Miyazaki A, Sato Y, Ohta T, Yamamoto Y, Aikawa M, Ohtsuka R, Yanagihara A, Iwata K, Shiratori T, Miyazawa Y.

Gan To Kagaku Ryoho. 2014 Apr;41(4):455-9. Japanese.

PMID:
24743360
18.

Eribulin mesylate in breast cancer.

Verdaguer H, Morilla I, Urruticoechea A.

Womens Health (Lond). 2013 Nov;9(6):517-26. doi: 10.2217/whe.13.61.

PMID:
24161305
19.

The European medicines agency review of eribulin for the treatment of patients with locally advanced or metastatic breast cancer: summary of the scientific assessment of the committee for medicinal products for human use.

Pean E, Klaar S, Berglund EG, Salmonson T, Borregaard J, Hofland KF, Ersbøll J, Abadie E, Giuliani R, Pignatti F.

Clin Cancer Res. 2012 Sep 1;18(17):4491-7. doi: 10.1158/1078-0432.CCR-11-3075. Epub 2012 Jul 24.

20.

Eribulin mesylate: a promising new antineoplastic agent for locally advanced or metastatic breast cancer.

Cortes J, Lorca R.

Future Oncol. 2011 Mar;7(3):355-64. doi: 10.2217/fon.10.186. Epub 2011 Mar 7.

PMID:
21375468

Supplemental Content

Support Center